miR‑324‑5p in oncology: Molecular mechanisms and clinical outlook (Review).
- 1The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, Hubei 443002, P.R. China.
- 2Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, College of Basic Medical Science, China Three Gorges University, Yichang, Hubei 443002, P.R. China.
Abstract
MicroRNAs (miRNAs or miRs) represent a class of regulatory non‑coding RNAs that control post‑transcriptional gene expression and influence multiple cancer‑associated biological processes. Among these molecules, miR‑324‑5p exhibits cancer type‑dependent functions, displaying tumor‑suppressive activity in certain types of malignancy while promoting oncogenic phenotypes in others. The molecular basis responsible for these opposing effects remains to be fully clarified. The present review summarizes evidence and integrates pan‑cancer analyses from The Cancer Genome Atlas to characterize the molecular mechanisms of miR‑324‑5p across different types of malignancies, with emphasis on experimental findings from animal models investigating tumor growth and metastasis. The clinical relevance of miR‑324‑5p, including its diagnostic, prognostic and therapeutic implications, is also discussed, together with challenges limiting clinical translation, particularly tumor‑specific delivery strategies and in vivo stability. Further elucidation of the molecular contexts governing miR‑324‑5p activity may facilitate its application in precision oncology.
Related
- The therapeutic landscape of cannabidiol: a systematic review of molecular mechanisms, clinical efficacy in oncology and neurology, and regulatory changes.
- A narrative review of barrier-matched engineering of macrophages for solid tumor immunotherapy: design logic, translational barriers and clinical outlook
- The Role of the OBSCN Gene in Cardiomyopathy: A Review of Molecular Mechanisms and Clinical Significance
- Local Corticosteroid Injection in Hand Surgery: A Review of Molecular Mechanisms, Steroid Selection, and Clinical Outcomes
- Novel strategies against drug-resistant tuberculosis: a comprehensive review from molecular mechanisms to clinical translation
BibTeX
@article{zhang2026mir3245p,
title = {{miR‑324‑5p in oncology: Molecular mechanisms and clinical outlook (Review).}},
author = {Kun Zhang and Zhen Xu and Yan Bin Luo and Chao Qi Liu and Yong Qin Zhou},
journal = {Oncology reports},
year = {2026},
month = oct,
doi = {10.3892/or.2026.9209},
url = {https://europepmc.org/article/MED/42885288},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - miR‑324‑5p in oncology: Molecular mechanisms and clinical outlook (Review).
AU - Kun Zhang
AU - Zhen Xu
AU - Yan Bin Luo
AU - Chao Qi Liu
AU - Yong Qin Zhou
PY - 2026
DA - 2026/10/16
JO - Oncology reports
DO - 10.3892/or.2026.9209
UR - https://europepmc.org/article/MED/42885288
AB - MicroRNAs (miRNAs or miRs) represent a class of regulatory non‑coding RNAs that control post‑transcriptional gene expression and influence multiple cancer‑associated biological processes. Among these molecules, miR‑324‑5p exhibits cancer type‑dependent functions, displaying tumor‑suppressive activity in certain types of malignancy while promoting oncogenic phenotypes in others. The molecular basis responsible for these opposing effects remains to be fully clarified. The present review summarizes evidence and integrates pan‑cancer analyses from The Cancer Genome Atlas to characterize the molecular mechanisms of miR‑324‑5p across different types of malignancies, with emphasis on experimental findings from animal models investigating tumor growth and metastasis. The clinical relevance of miR‑324‑5p, including its diagnostic, prognostic and therapeutic implications, is also discussed, together with challenges limiting clinical translation, particularly tumor‑specific delivery strategies and in vivo stability. Further elucidation of the molecular contexts governing miR‑324‑5p activity may facilitate its application in precision oncology.
SN - 1021-335X
SN - 1791-2431
ER -